San Diego-based mostly Viking Therapeutics marked by itself as a serious competitor during the weight loss drug current market in February following revealing promising knowledge from a mid-phase trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given as a weekly injection and in March the com